论文部分内容阅读
对17例原发性和转移性肝癌进行了肝动脉碘油栓塞化疗联合经皮门静脉穿刺灌注化疗。治疗后82．4％病人肿瘤缩小，显效41．2％，有效41．2％。一年生存率76.4％，二年生存率52．9％，三年生存率11.8％。40％病人甲胎蛋白明显下降。动、门脉联合治疗组明显优于单纯肝动脉栓塞化疗组。对本法的价值，门静脉插管途径，适应症和禁忌症进行了探讨。
Hepatic arterial iodized oil embolization chemotherapy combined with percutaneous portal vein puncture chemotherapy was performed on 17 cases of primary and metastatic liver cancer. 82.4% of patients after treatment tumor shrinkage, markedly effective 41.2%, effective 41.2%. The one-year survival rate is 76.4%, the two-year survival rate is 52.9%, and the three-year survival rate is 11.8%. AFP decreased significantly in 40% of patients. The combination of arterial and portal vein treatment was significantly better than the hepatic artery embolization chemotherapy group. The value of this method, portal vein catheterization, indications and contraindications were discussed.